Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CEST

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say theyll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers.

The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative.

Pfizers investigational therapies to be used in the trials include Bavencio (avelumab), a PD-L1 inhibitor; Glasdegib (PF-04449913), an investigational oral, smoothened (SMO) inhibitor; Mylotard (gemtuzumab ozogamicin), an antibody-drug conjugate; PF-04518600, an investigational OX40 agonist, and Utomilumab (a non-proprietary name for PF-05082566), an investigational CD137 agonist.

The first study is expected to enroll up to 188 patients with solid tumors, included in seven treatment groups of therapeutic agents alone or in combination with radiotherapy.

This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies, Dr. Aung Naing, associate professor of investigational cancer therapeutics at Houston-based MD Anderson and head of the solid tumor program, said in a press release. The studies are designed to hone in on specific combinations and tumor types, and explore unique mechanisms of response and resistance to immunotherapies. Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.

The second study, designed to enroll 159 patients with acute myeloid leukemia (AML), will have eight different treatment arms. In addition, three other studies will evaluate Pfizer agents in blood cancer patients.

This series of Phase 1b trials will involve an accelerated series of combination immunotherapy trials for acute myeloid leukemia (AML) and solid tumors, said Dr. Naval Daver, associate professor of leukemia at MD Anderson and leading investigator at the blood cancer clinical trial. Our aim is to deliver new therapeutic solutions to our patients through this uniquely designed clinical trial program.

Most of the trials are anticipated to be initiated before the end of 2017.

Pfizer believes that meaningful treatment advancements for patients with blood cancers will come from novel combinations of immuno-oncology agents and targeted therapies, said Dr. Chris Boshoff, senior vice-president and head of immuno-oncology, early development and translational oncology at Pfizer. We are delighted to work with MD Anderson one of the worlds best cancer research institutions to explore unique combinations that may have a significant impact for patients.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
08:13p PFIZER : Centreone Expands Contract Manufacturing To Nagoya, Japan
10:16a PFIZER : Biopharmaceutical Industry Creates Economic Opportunity for Americans
03:08a PFIZER : EDGE board approves incentives to entice Amazon warehouse, Pfizer jobs
10/18 PFIZER : Pfizers lorlatinib impresses in Phase II lung cancer trial
10/18 PFIZER INC. : Phase II Clinical Trial Of Lorlatinib Shows Promise
10/18 PFIZER : Pfizers son of Xalkori impresses in phase 2 NSCLC trial
10/18 PFIZER : Presents Full Results from Phase 2 Study of Next Generation Investigati..
10/18 PFIZER INC. : - New Ulcerative Colitis Data for XELJANZ at Upcoming Gastroentero..
10/18 RECKITT BENCKISER : to form two business units for better focus
10/17 PFIZER INC. (NYSE : PFE) Phase II Clinical Trial Of Lorlatinib Shows Promise
More news
News from SeekingAlpha
09:38a WHY ARE THESE 6 DOW STOCKS FAIRLY VA : Part 4 Of 5
02:45a A KISS Dividend Strategy Worth 15% A Year
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
Financials ($)
Sales 2017 52 676 M
EBIT 2017 19 837 M
Net income 2017 12 051 M
Debt 2017 24 101 M
Yield 2017 3,58%
P/E ratio 2017 19,26
P/E ratio 2018 16,94
EV / Sales 2017 4,51x
EV / Sales 2018 4,31x
Capitalization 213 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,2 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Dennis Arthur Ausiello Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER10.31%213 372
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924